Bahattin AVCI, Mustafa ÇAPRAZ, Caner GÜNAYDIN, Emine SEHMEN, Maruf BORAN, Demet YALÇIN KEHRİBAR, Mustafa CİHANGİROĞLU, Metin ÖZGEN

The assessment of the serum levels of TWEAK and prostaglandin F2α in COVID – 19

Background/aim: It is claimed that aberrant immune response has a more important role than the cytopathic effect of the virus in the morbidity and mortality of the coronavirus disease 2019 (COVID-19). We aimed to investigate the possible roles of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/Fn14 pathway and leukotrienes (LT) in uncontrolled immune response that occurs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Materials and methods: This study included 25 asymptomatic patients and 35 patients with lung involvement who were diagnosed with COVID-19 as well as 22 healthy volunteers. Lung involvement was determined using computed-tomography. Serum TWEAK, LTE4, and prostaglandin F2α (PGF2α) levels were determined. Results: Compared with the healthy control group, TWEAK, LTE4, and PGF2α levels were higher in the group of SARS-CoV-2 infection without lung involvement. In the group of SARS-CoV-2 infection with lung involvement, age, fibrinogen, sedimentation, C-reactive protein and ferritin, TWEAK, LTE4, and PGF2α levels were higher, and lymphocyte levels were lower compared with the asymptomatic group. Conclusions: In the study, TWEAK and LTE4 levels increased in cases with COVID-19. These results support that TWEAK/Fn14 pathway and LT may involved in the pathology of aberrant immune response against SARS-CoV-2. Inhibition of each of these pathways may be a potential target in the treatment of COVID-19.

PDF

___

1. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars Immunopathology 2017; 39 (5): 529-539. doi: 10.1007/s00281-017-0629-x
2. Huang C, Wang Y, Li X, Ren L, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506. doi: 10.1016/S0140- 6736(20)30183-5
3. Binqing Fu, Xiaoling Xu, Haiming Wei.Why tocilizumab could be an effective treatment for severe COVID-19? Journal of Translaional Medicine 2020; 18 (1): 164. doi: 10.1186/s12967- 020-02339-3
4. Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. Journal of Immunology 2010; 185 (3): 1593-1605. doi: 10.4049/jimmunol.0903555
5. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. Journal of Biological Chemistry 1997; 272 (51): 32401-32410. doi: 10.1074/ jbc.272.51.32401
6. Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. Journal of the American Society of Nephrology 2015; 26 (5): 1053-1070. doi: 10.1681/ASN.2014030233
7. Wen J, Xia Y, Stock A, Michaelson JS, Burkly LC et al. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. Journal of Autoimmunity 2013; 43: 44-54. doi: 10.1016/j.jaut.2013.03.002
8. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nature Reviews Drug Discovery 2008; 7 (5): 411-425. doi: 10.1038/nrd2488
9. Zimmermann M, Koreck A, Meyer N, Basinski T, Meiler F, Simone B. TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis. Journal of Allergy and Clinical Immunology 2011; 127 (1): 200-207. doi: 10.1016/j.jaci.2010.11.005
10. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007; 40 (1): 1-16.
11. Madrigal-Matute J, Fernandez-Laso V, Sastre C, LlamasGranda P, Egido J et al. TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovascular Research 2015; 108 (1): 139-147. doi: 10.1093/cvr/cvv204
12. Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clinical Therapeutics 2013; 35 (8): 1137-1149.
13. Sun F, Teng J, Yu P, Li W, Chang J et al. Involvement of TWEAK and the NF-κB signaling pathway in lupus nephritis. Experimental and Therapeutic Medicine 2018; 15 (3): 2611- 2619. doi: 10.3892/etm.2018.5711
14. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunological Reviews 2011; 244 (1): 99-114. doi: 10.1111/j.1600-065X.2011.01054.x
15. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. The Journal of the American Medical Association 1996; 275 (12): 931-936.
16. Beller TC, Maekawa A, Friend DS, Austen KF, Kanaoka Y. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. Journal of Biological Chemistry 2004; 279 (44): 46129-46134.
17. Davino-Chiovatto JE, Oliveira-Junior MC, MacKenzie B, Santos-Dias A, Almeida-Oliveira AR et al. Montelukast, leukotriene inhibitor, reduces LPS-induced acute lung inflammation and human neutrophil activation. Archivos de Bronconeumología 2019; 55 (11): 573-580.
18. Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. Journal of Experimental Medicine 2009; 206 (11): 2543-2555. doi: 10.1084/jem.20091240
19. Topaloğlu N, Olgun Yıldızeli Ş, Şener G, Laçin T, Şehirli Ö et al. Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin-induced pulmonary fibrosis. Türk Göğüs Kalp Damar Cerrahisi Dergisi 2018; 26 (4): 588-597.
20. Park JS, Kwok SK, Lim MA, Oh HJ, Kim EK et al. TWEAK promotes osteoclastogenesis in rheumatoid arthritis. The American Journal of Pathology 2013; 183 (3): 857-867.
21. Park MC, Chung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 2008; 37 (3): 173-178.
22. Chen N, Zhou M, Dong X, Qu J, Gong F et al. Epidemiological and clinical characteristics of 99 cases of 2 019 novel corona virus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507-513.
23. Luo P, Liu Y, Qiu L, Liu X, Liu D et al. Tocilizumab treatment in COVID‐19: A single center experience. Journal of Medical Virology 2020; 92 (7): 814-818. doi: 10.1002/jmv.25801
24. Chen T, Guo ZP, Fu LX, Cao N, Qin S. Anti-TWEAK monoclonal antibodies reduce vascular damage and leucocyte infiltration in a mouse model of cutaneous reverse passive Arthus reaction. Clinical and Experimental Dermatology 2016; 41 (8): 871-877. doi: 10.1111/ced.12912
25. Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I et al. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Cancer and Metastasis Reviews 2020; 8: 1-4. doi: 10.1007/s10555-020-09889-4
26. Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus and host antiviral defence: lessons from other pathogenic viruses. Emerging Microbes and Infections 2020; 9 (1): 558-570. doi: 10.1080/22221751.2020.1736644
27. Von Moltke J, Trinidad NJ, Moayeri M, Kintzer AF, Wang SB et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 2012; 490 (7418): 107-111. doi: 10.1038/nature11351
28. Johnson ZL, Chen J. Structural basis of substrate recognition by the multidrug resistance protein MRP1. Cell 2017; 168 (6): 1075- 1085.
29. Fidan C, Aydoğdu A. As a potential treatment of COVID-19: Montelukast. Medical Hypotheses 2020; 142: 109828. doi: 10.1016/j.mehy.2020.109828
30. Chen X, Zhang X, Pan J. Effect of montelukast on bronchopulmonary dysplasia (BPD) and related mechanisms. Medical Science Monitor 2019; 25: 1886-1893. doi: 10.12659/ MSM.912774
31. Westcott JY, Thomas RB, Voelkel NF. Elevated urinary leukotriene E4 excretion in patients with ARDS and severe burns. Prostaglandins, Leukotrienes & Essential Fatty Acids 1991; 43 (3): 151-158.